Literature DB >> 21745585

Alternative business models for drug discovery.

Barry A Bunin, Sean Ekins.   

Abstract

Mesh：

Year:  2011        PMID： 21745585     DOI： 10.1016/j.drudis.2011.06.012

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


× No keyword cloud information.
  5 in total

1.  Computational models for neglected diseases: gaps and opportunities.

Authors:  Elizabeth L Ponder; Joel S Freundlich; Malabika Sarker; Sean Ekins
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

2.  Precompetitive consortia in biomedicine--how are we doing?

Authors:  Barbara Mittleman; Garry Neil; Joel Cutcher-Gershenfeld
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

Review 3.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

4.  Bigger data, collaborative tools and the future of predictive drug discovery.

Authors:  Sean Ekins; Alex M Clark; S Joshua Swamidass; Nadia Litterman; Antony J Williams
Journal:  J Comput Aided Mol Des       Date:  2014-06-19       Impact factor: 3.686

5.  Collaboration for rare disease drug discovery research.

Authors:  Nadia K Litterman; Michele Rhee; David C Swinney; Sean Ekins
Journal:  F1000Res       Date:  2014-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.